The University of Iowa
The University of Iowa News Services Home News Releases UI in the News Subscribe to UI News Contact Us


Contact: TOM MOORE
8798 John Pappajohn Pavilion
Iowa City IA 52242
(319) 356-3945

Release: July 8, 1999

UI Cancer Center doctor elected to NSABP board to further breast cancer research

IOWA CITY, Iowa -- Peter Jochimsen, M.D., University of Iowa professor of surgery and director of surgical oncology at the UI Hospitals and Clinics, has been elected to the National Surgical Adjuvant Breast and Bowel Project (NSABP) Board of Directors.

Sponsored by the National Cancer Institute, the NSABP is an organization of research professionals concerned with studying, educating and developing clinical trials related to breast cancer.

Jochimsen said he does not view the appointment as a personal achievement, but rather as recognition of the skilled teams of breast cancer researchers at the UI Cancer Center.

"This is not an award to me," Jochimsen said, "It’s to the contributions made by the many departments and individuals here."

Jochimsen’s nomination and election to the board reflects the more than 35-year relationship the UI Hospitals and Clinics and NSABP have shared through clinical trials, research and the understanding of the natural history of breast cancer as well as patterns of intervention. The UI Cancer Center has actively participated in NSABP-sponsored clinical trials, such as the Breast Cancer Prevention Trial (BCPT). During the BCPT, UI Cancer Center researchers, in conjunction with several other participants, investigated the effectiveness of tamoxifen and determined that it was useful in preventing breast cancer in women at high risk for the disease.

As a board member, Jochimsen’s role will be to develop and evaluate studies that correlate with the NSABP’s primary focus in national cancer research. Jochimsen is intent on also maintaining a strong local link by keeping Iowa’s cancer care issues in mind.

"What I hope is that we get Iowans to more actively participate in the national agenda, rather than change the national agenda to fit Iowa," Jochimsen said.

A NSABP principal investigator since 1977, Jochimsen’s current project is the Study of Tamoxifen and Raloxifene (STAR). The study will examine how raloxifene measures against tamoxifen in preventing breast cancer. A total of 22,000 postmenopausal women nationwide with a high-risk of breast cancer will participate in STAR. For more information about STAR, call (319) 356-2778.